HAP Medicare Part B Drugs Requiring Step Therapy Last update 1/23/24

NON-Preferred Part B Drugs	Generic/Biosimilar name	Preferred Part B Drugs alternatives	Generic/Biosimilar Name
Step Therapy Required			
Rituxan	Rituximab	Truxima	Rituximab-abbs
Riabni	Rituximab-arrx	Ruxience	Rituximab-pvvr
Rituxan Hycela	Rituximab hyaluronidase		
Herceptin	trastuzumab	Kanjinti	Trastuzumab-anns
Ogivri	trastuzumab-dkst	Trazimera	Trastuzumab-qyyp
Ontruzant	trastuzumab-dttb		
Herzuma	trastuzumab-pkrb		
Herceptin Hylecta	trastuzumab/		
	hyaluronidase-oysk		
Remicade	Infliximab	Renflexis	Inflixmab-abda
Avsola	Infliximab-axxq	Inflecta	Infliximab-dyyb
Ixifix	Infliximab-qbtx		
Fulphila	Pegfilgrastim-jmbd	Neulasta	Pegfilgrastim
Ziextenzo	Pegfilgrastim-bmez	Udenyca	Pegfilgrastim-cbqv
Rolvedon	Eflapegrastim-xnst	Nyvepria	Pegfilgrastim-apgf
Stimufed	Pegfilgrastim-fpgk		
Fylnetra	Pegfilgrastim-pbbk		
Avastin*	Bevacizumab	Mvasi	Bevacizumab-awwb
*auth not required for eye		Zirabev	Bevacizumab-bvzr
related conditions			
Alymsys	Bevacizumab-maly		
Vegzelma	Bevacizumab-adcd		
Eylea	Aflibercept	Avastin	bevacizumab
Lucentis	Ranibizumab		
Beovu	Brolucizumab		
Byooviz	Ranibizumab-nuna		
Vabsymo	Faricimab-svoa		
Cimerli	Ranibizumab-eqrn		
Susvimo (implant)	ranibizumab	Lucentis	ranibizumab
Leqvio	Inclisiran	Repatha	evolocumab
Vyvgart	Efgartigimod-fcab	One of the following:	Azathioprine, mycophenolate,
Rystiggo	Rozanolixizumab-noli	azathioprine,	cyclosporine, or tacrolimus

HAP Medicare Part B Drugs Requiring Step Therapy Last update 1/23/24

		mycophenolate, cyclosporine, or tacrolimus	
Vyvgart hyrtulo	Efgartigimod alfa and	Vyvgart	Efgartigimod-fcab
	hyaluronidase-qvfc	Rystiggo	Rozanolixizumab-noli
Soliris	Eculizumab		
Ultomiris	Ravulizumab		
Izervay	Avacincaptad pegol	Syfovre	Pegcetacoplan
Entyvio	Vedolizumab	Hadlima	Adalimumab-bwwd
Skyrizi	Risankizumab		
Stelara	Ustekinumab		
Omvoh	Mirikizumab-mrkz		
Simponi Aria	Golimumab		
Cosentyx	Secukinumab		
	·	·	

Step Therapy requirements apply to certain Part B drugs. Step Therapy is a utilization tool that requires you to first try other drugs to treat your medical condition before we will cover the drug your physician may have initially prescribed. Currently, the plan has Step Therapy in place for the drugs listed above. The preferred drugs must be tried before the non-preferred product can be authorized or your doctor can tells us the reason the preferred drug is not right for you. The list will be updated as additional drugs are added to the Part B drug Step Therapy program.

Approval of a prior authorization request for a course of treatment is valid for as long as it is medically necessary to avoid disruptions in care. In accordance with applicable coverage criteria, medical history, and the treating provider's recommendation.

A 90-day transition period for any active course(s) of treatment for members new to the plan after starting a course of treatment, even if the service is furnished by an out-of-network provider. This includes enrollees new to a plan and enrollees new to Medicare. HAP will not disrupt or require reauthorization for an active course of treatment for new members for a period of at least 90 days.

Your doctor can submit a prior authorization for a drug on this list using the HAP Provider Portal on www.hap.org.